Squarepoint’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.44M | Sell |
44,143
-443,810
| -91% | -$65.8M | 0.01% | 1303 |
|
|
2026
Q1 | $64.3M | Buy |
487,953
+278,247
| +133% | +$36.9M | 0.08% | 262 |
|
|
2025
Q4 | $29.7M | Buy |
209,706
+169,225
| +418% | +$24.5M | 0.03% | 580 |
|
|
2025
Q3 | $5.68M | Sell |
40,481
-126,121
| -76% | -$17.1M | 0.01% | 1382 |
|
|
2025
Q2 | $20.9M | Buy |
+166,602
| New | +$19.1M | 0.02% | 743 |
|
|
2024
Q4 | – | Sell |
-68,369
| Closed | -$8.46M | – | 5353 |
|
|
2024
Q3 | $7.88M | Buy |
+68,369
| New | +$9.37M | 0.01% | 1099 |
|
|
2024
Q2 | – | Sell |
-30,806
| Closed | -$4.25M | – | 4450 |
|
|
2024
Q1 | $4.25M | Sell |
30,806
-49,375
| -62% | -$6.74M | 0.01% | 1573 |
|
|
2023
Q4 | $10.6M | Buy |
80,181
+51,830
| +183% | +$5.97M | 0.02% | 907 |
|
|
2023
Q3 | $3.19M | Sell |
28,351
-89,646
| -76% | -$9.44M | 0.01% | 1474 |
|
|
2023
Q2 | $11.1M | Sell |
117,997
-47,839
| -29% | -$4.67M | 0.03% | 608 |
|
|
2023
Q1 | $16.8M | Buy |
165,836
+132,314
| +395% | +$13.8M | 0.07% | 330 |
|
|
2022
Q4 | $4M | Sell |
33,522
-24,138
| -42% | -$2.83M | 0.02% | 951 |
|
|
2022
Q3 | $6.12M | Buy |
57,660
+44,656
| +343% | +$4.53M | 0.03% | 643 |
|
|
2022
Q2 | $1.27M | Sell |
13,004
-84,440
| -87% | -$7.79M | 0.01% | 1461 |
|
|
2022
Q1 | $9.13M | Buy |
97,444
+35,300
| +57% | +$2.99M | 0.04% | 474 |
|
|
2021
Q4 | $5.29M | Buy |
62,144
+44,657
| +255% | +$4.11M | 0.01% | 773 |
|
|
2021
Q3 | $1.68M | Sell |
17,487
-1,753
| -9% | -$166K | ﹤0.01% | 1295 |
|
|
2021
Q2 | $1.87M | Buy |
19,240
+16,393
| +576% | +$1.57M | 0.01% | 1226 |
|
|
2021
Q1 | $277K | Sell |
2,847
-1,197
| -30% | -$126K | ﹤0.01% | 2467 |
|
|
2020
Q4 | $388K | Sell |
4,044
-9,795
| -71% | -$946K | ﹤0.01% | 2015 |
|
|
2020
Q3 | $1.33M | Buy |
+13,839
| New | +$1.6M | 0.02% | 840 |
|
|
2020
Q2 | – | Sell |
-31,660
| Closed | -$2.74M | – | 2418 |
|
|
2020
Q1 | $2.74M | Sell |
31,660
-52,824
| -63% | -$5.17M | 0.07% | 363 |
|
|
2019
Q4 | $9.08M | Sell |
84,484
-81,220
| -49% | -$8.5M | 0.05% | 333 |
|
|
2019
Q3 | $14.9M | Buy |
165,704
+127,195
| +330% | +$11.9M | 0.13% | 191 |
|
|
2019
Q2 | $3.25M | Sell |
38,509
-73,922
| -66% | -$6.07M | 0.03% | 590 |
|
|
2019
Q1 | $9.9M | Sell |
112,431
-29,583
| -21% | -$2.47M | 0.1% | 233 |
|
|
2018
Q4 | $10.1M | Buy |
142,014
+134,539
| +1,800% | +$12.9M | 0.12% | 219 |
|
|
2018
Q3 | $919K | Buy |
7,475
+2,183
| +41% | +$248K | 0.01% | 1032 |
|
|
2018
Q2 | $520K | Buy |
5,292
+1,159
| +28% | +$104K | 0.01% | 1169 |
|
|
2018
Q1 | $343K | Sell |
4,133
-76,098
| -95% | -$6.43M | 0.01% | 1255 |
|
|
2017
Q4 | $6.22M | Buy |
80,231
+60,328
| +303% | +$4.11M | 0.11% | 215 |
|
|
2017
Q3 | $1.22M | Buy |
19,903
+15,465
| +348% | +$816K | 0.02% | 664 |
|
|
2017
Q2 | $204K | Buy |
+4,438
| New | +$215K | ﹤0.01% | 1298 |
|
|
2016
Q4 | – | Sell |
-24,611
| Closed | -$1.25M | – | 1867 |
|
|
2016
Q3 | $1.25M | Sell |
24,611
-41,289
| -63% | -$2.06M | 0.08% | 292 |
|
|
2016
Q2 | $3M | Buy |
+65,900
| New | +$3.03M | 0.19% | 121 |
|
|
2016
Q1 | – | Sell |
-5,300
| Closed | -$300K | – | 1353 |
|
|
2015
Q4 | $300K | Buy |
+5,300
| New | +$269K | 0.03% | 794 |
|
Other funds holding NBIX
Squarepoint's NBIX Position: Q2 2026 in Review
Squarepoint reduced its Neurocrine Biosciences (NBIX) stake by 91% in Q2 2026, selling an estimated $65.8M and leaving 44,143 shares worth $7.44M. The position accounts for 0.01% of the portfolio, ranked #1303.
Squarepoint first reported a position in NBIX in Q4 2015 and has held it in 36 quarters since. The position peaked at $64.3M in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Squarepoint held 44,143 shares of Neurocrine Biosciences worth $7.44M as of Q2 2026.
- Squarepoint sold 443,810 Neurocrine Biosciences shares in Q2 2026, an estimated $65.8M.
- Neurocrine Biosciences made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1303 holding.
- Squarepoint first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 36 quarters since.
- Squarepoint's Neurocrine Biosciences position peaked at $64.3M in Q1 2026.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.